long intergenic non-protein coding RNA 1480Genealiases: []
Q-omics provides the consensus-scored LINC01480 profile across patient tissues and cancer cell-line models. LINC01480 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01480 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LINC01480 RNA expression shows 20,452 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where LINC01480 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01480 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01480 survival associations across molecular data types. LINC01480 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01480 RNA expression–survival associations across cancer types. High LINC01480 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, UCEC, LUAD, SKCM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01480 RNA expression.
This table summarizes LINC01480 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01480. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01480 shows lower tumor expression in BRCA and higher tumor expression in KIRC, LUAD, LIHC, CHOL and STAD. The KIRC box plot shows higher LINC01480 RNA expression in tumor versus normal tissue (log2 FC = +0.907, t-test p < 0.001).
This table shows molecular features associated with LINC01480 in patient tissues and cancer cell lines. In patient samples, LINC01480 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
